How p53 differentially activates cell cycle arrest versus cell death remains poorly understood. Here, we demonstrate that upregulation of canonical pro-apoptotic p53 target genes in colon cancer cells imposes a critical dependence on the long splice form of the caspase-8 regulator FLIP (FLIP(L)), which we identify as a direct p53 transcriptional target. Inhibiting FLIP(L) expression with siRNA or Class-I HDAC inhibitors promotes apoptosis in response to p53 activation by the MDM2 inhibitor Nutlin-3A, which otherwise predominantly induces cell-cycle arrest. When FLIP(L) upregulation is inhibited, apoptosis is induced in response to p53 activation via a novel ligand-independent TRAIL-R2/caspase-8 complex, which, by activating BID, induces mitochondrial-mediated apoptosis.
Introduction
The mechanisms through which p53 activation differentially regulates cell survival (e.g. by initiating cell cycle arrest and DNA damage repair) and cell death (by promoting apoptosis) remain enigmatic 1 . Canonically, phosphorylation of the p53 N-terminus blocks its interaction with the E3 ubiquitin ligase Mouse Double Minute 2 (MDM2) (Momand et al, 1992; Shieh et al, 1997) reducing ubiquitination of the C-terminus and stabilizing p53. Stabilized p53 directly activates target genes to induce cell cycle arrest mediated by the cyclin-dependent kinase inhibitor p21/CDKN1A and other effectors (el-Deiry et al, 1993; Harper et al, 1993) . In the event of sustained stress and/or irreparable DNA damage, sequential post-translational modification of p53 is thought to direct p53 activity towards pro-apoptotic target genes, including those encoding Fas/CD95 (FAS) (Müller et al, 1998) , TRAIL Receptor 2 (TRAIL-R2/TNFRSF10B) also known as death receptor-5 (DR5) (Takimoto & el-Deiry, 2000) , Bax/BAX and the BH3 proteins Puma/BBC3 and Noxa/PMAIP1 (Nakano & Vousden, 2001; Villunger, 2003) . While we (McDade et al, 2014) and others have contributed to progress in identifying direct and indirect p53 target genes using ChIP-seq (Fischer et al, 2016) , the mechanisms underlying the switch from cell cycle arrest to cell death induction remains poorly understood.
Despite p53 being the most frequently mutated gene in cancer (Vogelstein et al, 2000) , approximately 50% of all cancers retain wild-type p53 (WT-p53) and typically circumvent or suppress p53's functions through alternative non-mutational mechanisms (Brown et al, 2009 ). Re-awakening the latent tumour suppressive functions in cancers retaining WT-p53 is an attractive clinical concept (Brown et al, 2009) , particularly since genetic reactivation is highly effective at inducing tumour regression in mouse models (Donehower & Lozano, 2009) . Given its central importance in suppressing p53, targeting the p53-MDM2 interaction has received significant attention and has led to the development of the selective small molecule inhibitors of MDM2 (MDM2i) such as Nutlin-3A (Vassilev, 2004) . While highly effective at stabilizing p53 (Brown et al, 2009) . such agents promote variable cellular fates depending on cell type in all but MDM2-amplified cells, in which they induce cell death (París et al, 2008; Tovar et al, 2006) . Pre-clinical and clinical development of the next generation of inhibitors of MDM2 (MDM2i) (and family member MDMX/MDM4) is ongoing (Wade et al, 2013) , and these agents are increasingly being combined with other therapies (Zhao et al, 2015) .
The observation that potent p53 stabilisation elicited by MDM2i is often insufficient to induce cell death suggests the existence of fundamental mechanisms that regulate the cell death-inducing effects of stabilized p53. Strategies targeting such p53-mediated cell death inhibitory mechanisms have potential to not only enhance MDM2i-induced cell death, but also to augment the efficacy of p53-induced cell death induced by radiotherapy and DNA damaging chemotherapies.
Acetylation of a dense cluster of lysine residues in p53's C-terminus, which are also target residues for ubiquitination by MDM2, has been suggested to enhance transactivation of pro-apoptotic target genes (Laptenko et al, 2015; Marouco et al, 2013; Tang et al, 2008a) . Nuclear Class I HDACs (HDAC1/2/3) have been shown to both interact with MDM2 to enhance p53 degradation and directly deacetylate the p53 C-terminus to influence its stability and transcriptional activity (Ito et al, 2002; Juan et al, 2000; Harms & Chen, 2007; Wang et al, 2012; Leboeuf et al, 2010) . HDAC activity is frequently deregulated in cancer, and cancer cells are typically more sensitive to HDAC inhibition than normal cells (Lee et al, 2010) ; hence, this class of epigenetic modifying enzymes has received significant attention as therapeutic targets, and HDAC inhibitors have achieved several clinical approvals despite rather limited understanding of their mechanisms-of-action (Guha, 2015) .
In this study, we demonstrate that selective inhibition of HDAC1/2/3 using the clinically relevant agent Entinostat (Trapani et al, 2017) synergises with direct and indirect p53-activating agents to activate apoptotic cell death. At the heart of this synergy, we identify the apoptosis regulator FLIP's long splice form (Fas-associated death domain (FADD)-like interleukin-1b-converting enzyme inhibitory protein) (FLIP(L)) as a direct p53 target gene and nodal determinant of cell fate following p53 activation.
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Entinostat modulates transcription of a subset of p53 target genes. To further assess the importance of p53-mediated transcription for the observed effects on cell death, we next evaluated the Nutlin-3A/Entinostat combination in HCT116 p53-null cells retrovirally reconstituted to express either the clinically relevant R248W DNA binding p53 mutant, a multiple Lys-Arg (8KR) acetylation mutant (Drosten et al, 2014) or p53-WT. Significant combinatorial effects of Nutlin-3A/Entinostat on cell death were detected only in the p53-null cells re-constituted with p53-WT ( Fig. 2a/b ), indicating that both DNA-binding and acetylation of p53 are required for the observed cell death phenotype.
Therefore, we next utilized mRNA-seq to investigate the transcriptional changes underpinning this synergy. Samples from HCT116 p53-WT and p53-null cells were collected 8 hours following treatment with Nutlin-3A, Entinostat or their combination, a timepoint at which p53 was stabilised and significant increases in expression of a range of direct p53 targets (including p21/CDKN1A, TRAIL-R2/TNFRSF10B and PUMA/BBC3) as observed by qRT-PCR; importantly however, as transcription may be indirectly suppressed in apoptotic cells, this 8-hour timepoint precedes activation of apoptotic cell death (Supplementary information, Fig. S2A-B ).
Treatment of p53-WT HCT116 cells with Nutlin-3A alone resulted in a significant increase (≥1.7-fold) in 393 genes ( Fig. 2c ; Supplementary information, Table S1 ), as expected, enriched for p53 signalling, apoptosis and direct p53 target genes (Supplementary information, Table S2a ). Even at this early time-point, 308 significantly repressed genes were identified; these were enriched for cell cycle and FOXM1/E2F4 targets potentially mediated through indirect suppression downstream of p21 activation (reviewed in (Fischer et al, 2014) ) (Supplementary information, Table S1 and Supplementary information, Table S2a ). No significantly altered genes were identified in the p53null model in response to Nutlin-3A ( Fig. 2c ), underlining the selectivity of this MDM2 inhibitor.
Conversely, there was significant overlap between the genes induced or repressed by Entinostat in both models, indicating that a large proportion of the effects of single agent Entinostat at this timepoint were not affected by p53 status (Supplementary information, Table S1 and Supplementary information, Table S2b ); most notable was p53-independent suppression of NFkB.
When we further compared the effects of the Nutlin-3A/Entinostat combination in p53-WT cells, only 31 genes were identified to be significantly upregulated relative to single agent treatments ( Fig. 2d and Supplementary information, Table S1/2d). It was notable that only one of these, Noxa/PMAIP1, was a canonical direct p53 induced pro-apoptotic target ( Fig. 2c -e, and confirmed by qRT-PCR in Supplementary information, Fig. S2b) . Surprisingly, 143 Nutlin-3A-induced genes were not significantly upregulated in combination-treated cells ( Fig. 2c and Supplementary information, Table   S2c ), of which 58 were significantly reduced compared to Nutlin-3A treatment alone ( Fig. 2f and Supplementary information, Tables S1/2). Interestingly, both gene lists were significantly enriched for tumour necrosis factor (TNF) and p53 signalling pathways ( Fig. 2f and Supplementary information, Table S2d ); this list included both pro-and anti-apoptotic regulators of death receptor signalling, for example the pro-apoptotic death receptor p53 target FAS/FAS (a canonical p53 target) and the regulator of death receptor-induced, caspase-8-mediated apoptosis CFLAR/FLIP ( Western blot analysis of parental p53-null HCT116 cells and daughter cells ectopically expressing wild-type (WTp53), R248W mutant or 8KR acetylation mutant p53. Cells were treated with 5 µM Nutlin-3A (N3A) for 24 hours (h) prior to treatment with 2.5 µM Entinostat (Entino) for an additional 24 h. (c) Differential gene expression analysis of mRNA-seq performed in HCT116 p53 wild-type (WT) and null cells from two independent experiments. RNA was extracted 8 h post treatment with DMSO, 5 µM Nutlin-3A, 2.5 µM Entinostat or their CFLAR  CMBL  CSF1  AMER1  FAS  CYP4F11  DSC3  APOBEC3C  IKBIP  DUOX1  GJB5  EHF  PHLDA3  DUSP11  IL12A  KLF15  TP53I3  GALNT5  LIF  LHX5  TRIAP1  ISCU  MMP14  METTL8  GPCR signalling  ITPKC  PLAU  ZNF219  ADGRG6  KCNN4  TAP1  Unknown  GPR87  MICALL1  COL17A1  CCDC90B  RGS20  PANK1  ncRNA  EPN3  Cytoskeleton  PLCL2  FAM83H-AS1  LBHD1  EPS8L2  PLCXD2  H19  LOC389906  FAM83H  PROM2  LOC101928402  NKX1-2  PSTPIP2  PTPRE  MIR34AHG  ZNF469  RFK  UNC5B-AS1  RFNG  RINL  SFN NDRG1  CGB7  CXCL8  ADRB2  NPAS1  CYTH4  ESRRB  ARRDC4  PLK3  HPX  HYAL1  OR51B4  PMAIP1  KCNJ14  KRT19  RAET1L  SERPINE1  Transcription  ncRNA  NPAS1  BREA2  ZNF425 LAMTOR5-AS1 MAFA-AS1 NEAT1 SNHG25 SNORA73B TINCR Functional genomics analyses identify CFLAR/FLIP as a direct HDAC1/2/3-dependent prosurvival target of p53. To investigate the mechanisms underlying Entinostat-enhanced, p53dependent cell-death, we evaluated the effect of Nutlin-3A in HCT116 cells transfected with a panel of siRNAs targeting 37 core cell death regulators ( Fig. 3a ). Aligning these results with the mRNAseq dataset identified CFLAR/FLIP as a potential nodal regulator of p53-induced death since its depletion significantly enhanced the effects of Nutlin-3A on viability and its mRNA expression was induced in a p53-dependent manner, but attenuated by Entinostat co-treatment ( Fig. 2e, 3a and Table S1 /2). Moreover, we also identified sgRNAs targeting CFLAR/FLIP as one of the top sensitizers to Nutlin-3A in gene-level MAGeCK analysis of a genomewide CRISPR screen ( Fig. 3b and Supplementary information, Table S3 ) further supporting a nodal role for CFLAR/FLIP in promoting survival in cells in which p53 is activated. As a quality control for the screen, sgRNAs targeting p53 and CDKN1A/p21 were identified as mediators of resistance to Nutlin-3A (Supplementary information, Fig. S3a ). Re-analysis of previous ChIP-seq data from our group in human foreskin keratinocytes treated with cisplatin (McDade et al, 2014) or public MCF7 breast cancer cells treated with Nutlin-3A (Nikulenkov et al, 2012) identified direct, treatment-induced binding of p53 to the CFLAR/FLIP promoter (Supplementary information, Fig. S3b ), and this was confirmed in HCT116 cells following treatment with Nutlin-3A ( Fig. 3c ). This coincided with induction of transcription of both the long FLIP(L) and short splice forms FLIP(S) (the latter expressed at significantly lower levels) as detected by qRT-PCR ( Fig. 3d ). This analysis also confirmed that Nutlin-3A-induced CFLAR/FLIP mRNA upregulation was attenuated by co-treatment with Entinostat, with similar effects observed in the LoVo model (Supplementary information, Fig. S2c ).
Unknown
Changes in CFLAR/FLIP mRNA expression in HCT116 p53-WT cells were reflected at the protein level for FLIP(L) but not for FLIP(S), which was expressed at a much lower level than the long splice form ( Fig. 3e and Supplementary information, Fig. S3c ). Since CFLAR/FLIP is a known NFkB target gene (reviewed in (Riley et al, 2015) ) and our mRNA-seq analysis indicated the potential for Entinostat to significantly suppress components of the NFkB pathway in both p53-WT and -null cells (Supplementary information, Table S2b ), we next evaluated whether NFkB contributed to changes in FLIP expression. Time-course analysis in both HCT116 and LoVo cells indicated that FLIP(L) protein expression was induced at early time-points coincident with or even preceding p21 upregulation ( Fig. 3f and Supplementary information, Fig Fig. 3g ). At later timepoints, the FLIP(L) cleavage product p43-FLIP was also detectable (Fig. 3g ); when FLIP(L) forms FADD-dependent heterodimers with procaspase-8, it is cleaved in its C-terminus between its large and small pseudo-catalytic domain (Humphreys et al, 2018) . Altogether, these results establish FLIP and particularly FLIP(L) as a direct p53 target that is induced in an independent manner that is independent from its canonical regulation by NFkB. BBC3  TNFRSF10B  BIK  BIRC3  PMAIP1  STAT3  FAS  BAX  CFLAR  TNFRSF10A  BCL2L1  BAK1  CASP10  CASP2  BAD  ATG3  CASP3  TP53  XIAP  BID  BCL2L2  BOK  BCL2  HRK  FADD  BMF  BCL2L11 BIRC2 The best described function of FLIP is its role as a regulator of caspase-8-dependent apoptosis; however, whether FLIP(L) acts an inhibitor or activator of caspase-8 remains a matter of debate. We therefore extended our analyses to a CRISPR-Cas9 caspase-8-deficient HCT116 model (Paek et al, 2016) , which was found to be significantly more resistant to the cell death inducing effects of FLIP(L) silencing in cells treated with Nutlin-3A for 24 h than control caspase-8-expressing cells ( Nutlin-3A induces formation of a ligand-independent TRAIL-R2 complex. FLIP and FADD regulate procaspase-8 processing and activation at death-inducing signaling complexes (DISCs) formed by death receptors and the cytoplasmic ripoptosome formed by RIPK1 (Riley et al, 2015) . depleted cells, we re-examined the mRNA-Seq data for the effects of Nutlin-3A and Entinostat on death receptor expression. FAS/Fas and TNFRSF10A/DR4/TRAIL-R1 were both upregulated in response to Nutlin-3A, but this increase was suppressed by co-treatment with Entinostat (data viewable in HDAC_visualiseR Shiny App). TNFRSF10B/DR5/TRAIL-R2, a known direct p53 target (Takimoto & el-Deiry, 2000) , was expressed at a higher level than the other 2 death receptors and was as expected significantly upregulated in response to Nutlin-3A; however in this case, the upregulation was unaffected by co-treatment with Entinostat. RIPK1 was expressed at a low level that was unaffected transcriptionally by either treatment. Notably, RNAi-mediated downregulation of TRAIL-R2, but not the other death receptors nor RIPK1 (data not shown), significantly rescued the cell death induced by treatment with Nutlin-3A in combination with siFLIP(L) and did so to a similar extent as silencing caspase-8 and p53 ( Fig. 5A ). Of note, cleavage and activation of BID was also reduced in TRAIL-R2-and caspase-8-depleted cells (Fig. 5a ). These results were confirmed in 2 independent p53-WT CRC models (Supplementary information, Fig. S5a ) and using an HCT116 model in which TRAIL-R2 expression was deleted by CRISPR-cas9 ( Fig. 5b/c ). Silencing TRAIL-R2 or CASP8 (and as expected p53) in HCT116 cells also partially inhibited apoptosis signaling in response to Nutlin-3A/Entinostat co-treatment ( Fig. 5d ).
Canonically, TRAIL-R2-mediated activation of caspase-8 and apoptosis involves binding of its ligand TRAIL (Humphreys et al, 2018) ; it was therefore highly notable that co-incubation with a TRAIL neutralizing antibody failed to rescue cell death induced by Nutlin-3A/siFLIP(L) (Fig. 5e ), a result Collectively, these results suggested formation of a novel ligand-independent TRAIL-R2/FLIP(L) complex in cells treated with Nutlin-3A. To assess this, we isolated TRAIL-R2 complexes formed in response to Nutlin-3A (in the absence of ligand) using the humanized anti-TRAIL-R2 antibody Conatumamab (AMG655). This analysis indicated that Nutlin-3A indeed stimulates formation of a complex between TRAIL-R2 and FADD, FLIP(L) and caspase-8 ( Fig. 5g ). Importantly, both FLIP(L) and caspase-8 are processed in this ligand-independent complex (indicative of formation of catalytically active dimers) and depletion of FLIP(L) using siRNA enhanced caspase-8 recruitment ( Fig. 5g) , consistent with the apoptotic phenotype observed in FLIP(L)-depleted, Nutlin-3A-treated cells. Thus, acute p53-mediated upregulation of FLIP(L) prevents caspase-8-dependent apoptosis induction mediated in a TRAIL-independent manner by TRAIL-R2, which is concomitantly upregulated in response to Nutlin-3A.
Later cell death is induced by Nutlin-3A/siFLIPL in the absence of caspase-8. At later timepoints (48 hours), the apoptotic cell death induced by Nutlin-3A/siFLIP(L) was notably less caspase-8dependent than at 24 hours ( Fig. 6a ). Moreover, processing of procaspase-10, a paralog of procaspase-8 and FLIP, was observed in both CASP8 -WT and -null cells in response to Nutlin-3A/siFLIP(L) (Fig. 6a ). Similar to FLIP(L), the role of caspase-10 as a promoter or inhibitor of apoptosis has been controversial (Horn et al, 2017a) ; we therefore investigated whether caspase-10 could compensate for the loss of caspase-8 at later time-points. In siRNA depletion experiments, siCASP10 partially rescued PARP cleavage induced by Nutlin-3A/siFLIP(L) in caspase-8-deficent cells and did so to a similar extent as siTRAIL-R2 ( Fig. 6b ), indicating that this later cell death is also partly TRAIL-R2-dependent. To confirm these results, we generated caspase-10 knockout models in caspase-8-proficient and -deficient backgrounds using CRISPR-Cas9 ( Fig. 6c/d ). In the Caspase-8 wild-type setting, loss of caspase-10 did not significantly reduce the levels of apoptosis induced by Nutlin-3A/siFLIP(L) ( Fig. 66c/d ). However, in caspase-8-WT cells, loss of caspase-10 further decreased the cell death induced by Nutlin-3A/siFLIP(L) at 48 hours ( Fig. 6c/d compared to Nutlin-3A treatment alone (Fig. 6e-g and Supplementary information, Fig. S6E-G) .
Collectively, this implies that FLIP(L) has functions that are independent of its canonical interactome.
The cell death induced by Nutlin-3A/siFLIP(L) at the later timepoint was however completely attenuated in cells lacking BAX and BAK even though BID was cleaved in this model ( Fig. 6h and was particularly apparent in cell lines in which apoptosis induction was inhibited. We therefore assessed whether PUMA was responsible for mediating the cell death phenotype induced at later timepoints by Nutlin-3A/siFLIP(L) in cells lacking caspase-8/10. In caspase-8/10-deficient models, PUMA was again found to be upregulated in response to Nutlin-3A/siFLIP(L) (Fig. 7a-c) . Cosilencing of PUMA indeed rescued the residual cell death induced by Nutlin-3A/siFLIP(L) in caspase-8/10-deficient models, but had no effect in caspase-8-and/or caspase-10-proficient cells (Fig. 7a-c ).
Further analysis of mRNA expression indicated that silencing FLIP(L) enhanced Nutlin-3A-induced upregulation of PUMA mRNA (Fig. 7d ), which notably was concomitant with suppression of CDKN1A/p21 mRNA induction, consistent with observations made at the protein level ( Fig. 7b, 6a/d,   5d ). Collectively, these results indicate that p53-mediated upregulation of FLIP(L) suppresses p53mediated upregulation of PUMA and promotes p53-mediated upregulation of p21, suggestive of a novel negative feedback from FLIP(L) to suppress PUMA-mediated apoptosis and promote p21mediated cell cycle arrest.
Silencing PUMA also significantly but incompletely rescued the cell death induced by Nutlin-3A/Entinostat in caspase-8/10-deficient cells (Fig. 7e/f ). As has been previously reported (Inoue et al, 2007) , another BH3-only protein BIM was significantly upregulated in response to Entinostat; moreover, we found that this induction was p53-independent (Supplementary information, Fig. S7h ).
Notably, co-silencing BIM alongside PUMA completely rescued the cell death induced by Nutlin-3A/Entinostat in caspase-8/10-deficient cells (Fig. 7e) . The involvement of BIM in mediating the effects of Entinostat/Nutlin-3A likely explains the greater dependence of this combination on BAX than the siFLIP(L)/Nutlin-3A combination (Fig. 6i/j) ; BIM preferentially activates BAX, whereas BID preferentially activates BAK (Sarosiek et al, 2013) . However, the resistance of p53-null cells to Entinostat/Nutlin-3A ( Fig. 1/2 ) shows that this upregulation of BIM is insufficient to drive apoptosis in the absence of p53-mediated upregulation of other components of the apoptotic machinery. BIM upregulation was also observed in siFLIP(L)-treated caspase-8/10 deficient cells (Fig. 2b) ; however, this effect was abrogated in PUMA-depleted cells. Moreover, BIM upregulation in FLIP(L)-depleted cells was post-transcriptional (data not shown), suggesting that this effect may be a result of interplay between Bcl-2 family members, potentially caused by PUMA upregulation. 
Discussion
In the 50% of tumors harboring p53-WT, its function is typically suppressed; therefore, reactivation of p53's latent tumor suppressive functions in these cancers is a highly attractive therapeutic approach (Brown et al, 2009 ). However, despite the development of selective p53 activating agents (best exemplified by MDM2 inhibitors, e.g. Nutlin-3A), none of these molecules have yet been clinically approved (Khoo et al, 2014) . This potentially stems from the fact that these agents primarily induce cell cycle arrest rather than cell death in all but MDM2-amplified cancer cells (París et al, 2008; Tovar et al, 2006) . Indeed, the mechanisms underlying the switch from p53-induced cell cycle arrest to p53-induced cell death remain surprisingly poorly understood, and strategies that enhance cell death induced by direct (e.g. MDM2 inhibitors) and indirect (e.g. DNA damaging agents) p53
activating agents are highly sought after.
HDACs have been shown to regulate acetylation of p53 in particular in its lysine-rich C-terminus, the hyper-acetylation of which has been correlated with enhancement apoptotic cell death (Knights et al, 2006; Mellert et al, 2011; Sykes et al, 2006; Brochier et al, 2013; Laptenko et al, 2015) . HDAC2
has been reported to suppress p53 activity (Wagner et al, 2014) and is upregulated in CRC as a consequence of inactivation of the adenomatous polyposis coli (APC) tumour-suppressor gene, which is mutated in ~80-85% of sporadic colorectal cancers (Zhu et al, 2004) . Thus, we investigated the possibility that HDAC inhibition may enhance cell death induced by Nutlin-3A in CRC cells.
Indeed, clear enhancement of CRC cell death was observed when Nutlin-3A was combined with the clinically relevant Class-I HDAC inhibitor Entinostat. Furthermore, we found that "non-acetylatable" p53 was unable to induce cell death in response to Nutlin-3A and Entinostat co-treatment. In contrast to our expectations, mRNA-Seq analyses revealed that Entinostat enhanced Nutlin-3A-induced expression of only one canonical p53 pro-apoptotic target, Noxa/PMAIP1. Paradoxically, we found that Entinostat suppressed Nutlin-3A-induced expression of a subset of apoptotic targets, most notably FLIP/CFLAR, which we identified as a novel direct p53 target gene and which our functional siRNA and CRISPR screens identified as a nodal suppressor of Nutlin-3A-induced cell death.
Importantly, recent reports suggest that Class-I HDACi exert a significant proportion of their transcriptional modulatory effects through suppression of super-enhancer driven genes (Gryder et al, 2019) , with maximal suppression requiring inhibition of HDAC1/2/3, consistent with our siRNA analysis, which showed that suppression of all 3 Class-I HDACs was required for maximal induction of Nutlin-3A-induced apoptosis (Fig. 1c ).
We Notably, at later timepoints post Nutlin-3A treatment, significant levels of caspase-8-independent cell death were induced in FLIP(L)-depleted cells. We initially examined whether this was mediated by the caspase-8 and FLIP(L) paralog caspase-10. Similar to FLIP(L), the role of caspase-10 at the DISC is controversial, with it described as being able to compensate for lack of caspase-8 (Wang et al, 2001) unable to compensate for lack of caspase-8 (Sprick, 2002) and acting to inhibit caspase-8-mediated apoptosis (Horn et al, 2017b) . Our results were interesting: in the presence of caspase-8, deletion of caspase-10 moderately enhanced cell death in siFLIP(L)/Nutlin-3A-treated cells (although this failed to reach significance); whereas in the absence of caspase-8, co-deletion of caspase-10 significantly decreased apoptosis induction. These results indicate that caspase-10 has a minor inhibitory role in caspase-8-proficient cells (potentially by interfering with procaspase-8 homo-dimerization, a prerequisite for caspase-8 activation, but can itself drive apoptosis in siFLIP(L)/Nutlin-3A-treated cells in the absence of caspase-8 (albeit less efficiently). We found that caspase-10-deficiency also enhanced IZ-TRAIL-induced apoptosis; however, unlike apoptosis induced by siFLIP(L)/Nutlin-3A, we found no evidence for caspase-10 being able to induce apoptosis in response to IZ-TRAIL in caspase-8-deificient HCT116 cells (Supplementary information, Fig. S4f) .
This difference between ligand-dependent and ligand-independent activation of TRAIL-R2 may be due to p53-mediated upregulation of caspase-10, which we found was induced in both RNA-seq and protein analyses along with FLIP in response to Nutlin-3A (Supplementary information, Table S1 , HDAC visualiseR and Fig. 6b/d) .
Even The mechanism of cell death induced by the combination of Nutlin-3A with Entinostat was almost identical to that induced by Nutlin-3A/siFLIP(L) with a couple of notable exceptions. As previously reported (Inoue et al, 2007) and confirmed by us, Entinostat significantly upregulates BIM; this upregulation has been suggested to be mediated by acetylation of FOXO1 (Yang et al, 2009 ). Along with PUMA, BIM was found to be responsible for the apoptosis induced by Nutlin-3A/Entinostat when the extrinsic apoptotic pathway was blocked by caspase-8/-10 co-deletion. As BIM preferentially activates BAX, and BID preferentially activates BAK (Sarosiek et al, 2013) , this explains the differential dependence of the Nutlin-3A/Entinostat and Nutlin-3A/siFLIP(L) combinations on BAX and BAK respectively.
We speculate that acute concomitant induction of FLIP(L) and TRAIL-R2 in response to p53 stabilization enables epithelial cells to be primed to undergo apoptosis, whilst preventing induction of apoptosis en masse, which in epithelial cells would result in barrier dysfunction. Rapid commitment to cell death would then occur in response to secondary signaling event(s) (absent in cells treated with selective MDM2 inhibitors), which overcome FLIP(L)'s anti-apoptotic functions. In the context of more complex signals such as DNA damaging chemotherapy that result in oscillating levels of p53, its negative regulators and targets, modifications to p53 not induced by Nutlin-3A (such as acetylation) as well as activation/inactivation of additional signaling pathways may lead to downregulation of FLIP(L) expression, thereby triggering commitment to apoptosis. These findings complement single cell studies that demonstrated the importance of late induction of inhibitors of apoptosis (IAP) family in raising the apoptotic threshold to block apoptosis in the context of suboptimal p53 stabilisation by platinum (Paek et al, 2016) . Furthermore, the specific and rapid upregulation of the long FLIP(L) splice form in response to p53 stabilisation may act not only to put the brakes on apoptosis, but also to inhibit the more pro-inflammatory RIPK1-dependent necroptotic cell death as the FLIP(L)-caspase-8 heterodimer can cleave RIPK1 (van Raam and Salvesen, 2012) .
In summary, this work has uncovered novel, clinically-relevant biology, in which early p53-mediated upregulation of FLIP(L) prevents commitment of CRC cells to apoptosis by blocking activation of caspase-8/10 from a p53-induced ligand-independent TRAIL-R2 complex and by suppressing p53mediated induction of PUMA (Fig. 7g) . From a cancer therapeutics point of view, we show the potential of combining Nutlin-3A (and likely 2 nd generation MDM2 inhibitors) with Class-I HDAC inhibitors for the treatment of p53-WT CRC (and potentially other p53-WT cancers), and identify FLIP(L) as a critical p53-induced signaling node, the inhibition of which is necessary to promote apoptosis in response to MDM2 inhibition.
Materials and Methods
Reagents and Plasmids. The following reagents were used: SAHA (Vorinostat; Selleck Chemicals, Suffolk, UK), Nutlin-3a (MedChemExpress, Middlesex, NJ) and Entinostat (MS-275; Selleck Chemicals, Suffolk, UK). 5-Fluorouracil (5-FU) and Oxaliplatin were obtained as kind gifts from the Belfast City Hospital Cancer Centre. The WTp53, R248W and 8KR expression plasmids (pWZL-Blast vector) (Drosten et al, 2014) were kind gifts received from Mariano Barbacid, CNIO, Madrid.
Antibodies.
The following Western blot antibodies were used: PARP, Phospho Histone H2AX (S139), Phospho Western blot analyses. Western blot analyses were performed using samples lysed in RIPA Buffer supplemented with PhosSTOP (Roche) and Protease Inhibitor Cocktail (Roche). Equal amounts of protein (20-40 µg/well) were resolved by SDS-PAGE using the Novex system (Invitrogen) and transferred to nitrocellulose membranes using iBLOT (Invitrogen). Westerns were developed digitally using a FluorChem SP imaging system (Alpha Innotech) or the G:BOX ChemiXX6 gel doc system (Syngene).
Immunoprecipitations. The DR5 DISC assay was performed as previously described (Majkut et al, 2014 fetal bovine serum, 50U/ml penicillin and 0.1mg/ml streptomycin. All cells were maintained at 37 0 C in a 5% CO2 humidified atmosphere and were regularly screened for the presence of mycoplasma using the MycoAlert Mycoplasma Detection Kit (Lonza, Basel, Switzerland).
Stable cell lines.
LoVo cells were transduced with retroviral pSUPER vectors expressing control or p53 shRNA under puromycin selection (0.5 µg/mL) as described previously (McDade et al, 2011) .
HCT116 p53-null cells were transduced with retroviral pWZL-Blast vectors expressing WT, R248W
and 8KR p53 proteins and selected in 10 µg/mL Blasticidin (Sigma). HCT116 clones expressing a mutant form of the human IкB-α with serine 32 and 36 mutated into alanine (IкB-α SR) were generated using pRc-β-actin-IкB-α plasmid (SR) or a control pRc-β-actin plasmid (EV) (Luo et al, 2004) as previously described (Ryan et al, 2014) .
CRISPR Cell line generation. HCT116 FADD CRISPR cell lines were generated by retroviral infection with pLentiCRISPR with guide RNA targeting FADD;
GCGGCGCGTCGACGACTTCG. Mixed population of cells were established following selection with 1 µg/ml puromycin. Cells were clonally selected for complete knockdown by Western blot.
HCT116 caspase-8/caspase-10 double knockout cells were generated by retroviral infection of HCT116 caspase-8 CRISPR cells with pLentiCRISPRblast containing guide RNA targeting caspase-10:GACTGCTGCCCACCCGACAA. Mixed population of cells were established following selection with blasticidin (10 µg/ml). Cells were clonally selected for complete knockdown, verified by Western blot. and HDAC2 were commercially purchased (Qiagen). The siRNA against HDAC3 was described previously (Senese et al, 2007) . The siRNA targeting p53 was purchased from Dharmacon (Dharmacon, Lafayette. CO) and has the following sequence: GUUCCGAGAGCUGAAUGAdTdT.
ON-TARGETplus SMARTpool siRNA reagent targeting Caspase-10 (catalog # L-004402-00), PUMA (catalog # L-004380-00), NOXA (catalog # L-005275-00) and BIM (catalog # L-004383-00)
were commercially purchased from Dharmacon. siRNA transfections were performed as previously described (Majkut et al., 2014) .
Apoptosis siRNA screen. siGENOME® SMARTpool® siRNA Library (Dharmacon) containing 4 sequences directed against each of 37 cell death related genes and controls were obtained in Echoqualified 384-well polypropylene source plate (Labcyte, Sunnyvale, CA). siRNA pools were resuspended to a final concentration of 2 µM and 150nL of 2 µM siRNA stocks were dispensed into 384-well assay plates using an Echo 525 Series Liquid Handler (Labcyte, Sunnyvale, CA), 10 µL of a 1:167 mix of RNAiMAX (Life Technologies) added, incubated for 1 h at room temperature, before addition of 900 cells per well in 20 µL of Optimem and incubated overnight (final concentration siRNA = 10 nM) The following day the transfection mixture was replaced with groWTh media with or without 2.5 µM Nutlin-3A. The plate was then incubated for 72 h at 37°C before measuring cell viability using CellTitreGlo reagent (Promega).
Reverse transcription and quantitative RT-PCR analyses. Cells were homogenised using
TriPure Isolation Reagent (Roche) and total RNA was then extracted using the PureLink RNA Mini Kit (Ambion). Alternatively, cells were lysed in buffer RLT plus (Qiagen) and RNA extracted using the RNeasy Plus extraction kit (Qiagen) as per manufacturer's instructions. Subsequently, 2500ng
of RNA was processed using the TURBO DNA-free Kit (Ambion) to remove contaminating genomic DNA, and 500ng of DNA-free RNA was used to generate cDNA using the High-Fidelity cDNA Synthesis Kit (Roche). Quantitative RT-PCR (RT-qPCR) was conducted using LightCycler 480 SYBR Green Master (Roche). The primers used are presented in Supplemental Supplementary Table4.
Chromatin Immunoprecipitation (ChIP) and quantitative RT-PCR analyses. Cell fixation was carried out as previous described (McDade et al, 2014) . Chromatin was isolated from 5 million cells and Chromatin immunoprecipitation for p53 was performed with DO-1 antibody (Santa Cruz Biotechnology) performed using the iDeal ChIP-seq kit for Transcription Factors according to manufacturer's instructions (Diagenode) with direct method on the Diagenode IP-Star and purified with iPURE kit (Diagenode). Quantiitative PCR and fold enrichment estimated for CFLAR promoter estimated compared to negative control region ( Supplementary Table 5 ) using as previously described (McDade et al, 2014) .
RNA-sequencing. Total RNA was extracted as above, and 1 µg of each RNA sample was used as a template to generate cDNA using the TruSeq Stranded mRNA Library Prep Kit (Illumina), following the manufacturer's instructions for the low-sample (LS) protocol. These first-stranded cDNA samples were processed to barcoded cDNA libraries using an automated IP-Star (Diagenode), amplified, quantified and pooled and sequenced to yield 20-30M paired-end 75BP reads per sample on an Illumina Nextseq 500. FASTQ files were de-multiplexed, aligned to hg19 reference genome using BoWTie2 in using Basespace RNA-seq app (Illumina), resulting .bam files were mapped to RefSeq transcripts using Patek Genomics Suite (Partek) and gene-level RPKM normalized output used for differential gene expression analysis. Transcripts were filtered with an RPKM threshold of ≥0.5 in 50% of samples (12,411 genes) and significantly upregulated and downregulated transcripts identified using 3-way ANOVA with a mean RPKM fold-change threshold of ≥1.7x and False Discovery Rate (FDR) of 0.05. Resulting analyses can be visualised and downloaded from our Shiny app (functionalgenomicsgroup.shinyapps.io/HDAC_visualiseR/). Pathway analyses were conducted using the Enrichr online tool (Kuleshov et al, 2016) . The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al, 2002) (Li et al, 2014) Flow cytometry analyses. Cells were harvested, and Annexin V and propidium iodide (PI) positivity analysed as previously described (Majkut et al, 2014) . Analysis was carried out on either the BD LSR-II flow cytometer (BD Biosciences) or the BD Accuri TM C6 flow cytometer (BD Biosciences were measured twice weekly using the formula: 1/2(a x b 2 ), where b is the shorter measurement.
Once tumours were established (average volume 100mm 
Statistical Analysis
Statistical analyses were performed using Prism 8.0 software (Graphpad). Experimental results were compared using a two-tailed Students t-test, One-Way ANOVA with multiple comparisons and Bonferroni Post-test, Two-Way ANOVA or Three-Way ANOVA where appropriate; *p ≤ 0.05 **p ≤ 0.01 ***p ≤ 0.001 and ****p ≤ 0.0001. Experiments were replicated at least 2 times and in most cases 3 or more. Supplementary Fig. 1. HDAC Supplementary Fig. 4. Nutlin-3a RPKM values for BCL2L11/BIM and BID from mRNA-seq performed in HCT116 p53-WT and null isogenic cells (described in Fig. 2(c 
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